Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use / Q000633:toxicity*; D004341:Drug Evaluation; D015251:Epirubicin; D006801:Humans; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013237:Stereoisomerism
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D004317:Doxorubicin